48 related articles for article (PubMed ID: 9483405)
1. [The role of blockage of various M-cholinoreceptor subtypes in induction of tachycardia in rats].
Kosmachev AB; Lychakov AV; Saunkina IuA; Fil'ko OA; Chigareva SM
Eksp Klin Farmakol; 1997; 60(5):44-6. PubMed ID: 9483405
[TBL] [Abstract][Full Text] [Related]
2. [The role of the blockade of separate subtypes of muscarinic receptors in realizing the antidotal effect of m-cholinolytics in dimethyl dichlorovinyl phosphate poisoning].
Kosmachev AB; Beliaev VA; Fil'ko OA; Podosinovikova NP; Solov'eva NE; Titkova TA
Eksp Klin Farmakol; 1999; 62(4):55-8. PubMed ID: 10513339
[TBL] [Abstract][Full Text] [Related]
3. [The role of M-cholinoreceptor subtypes in heart rhythm disturbances of various etiology].
Kosmachev AB; Fil'ko OA; Petrov VV
Eksp Klin Farmakol; 2002; 65(1):34-6. PubMed ID: 12025782
[TBL] [Abstract][Full Text] [Related]
4. [The selectivity and protective properties of m-cholinolytics in dichlorodivinylphosphate poisoning].
Kosmachev AB; Iankhotova MB; Kosmacheva IM
Eksp Klin Farmakol; 1992; 55(3):56-8. PubMed ID: 1458168
[TBL] [Abstract][Full Text] [Related]
5. [Effect of biotransformation on the receptor selectivity of muscarinic antagonists in vivo].
Kosmachev AB; Titkova TA; Fil'ko OA; Libman NM
Eksp Klin Farmakol; 2000; 63(4):13-6. PubMed ID: 11022298
[TBL] [Abstract][Full Text] [Related]
6. [Effect of M3-choline receptor blockade on the ability of muscarinic antagonists to prevent catalepsy induced by haloperidol in rats].
Kosmachev AB; Beliaev VA; Khrabrova AV; Libman NM; Dolgo-Saburov VB
Eksp Klin Farmakol; 2001; 64(4):10-2. PubMed ID: 11589099
[TBL] [Abstract][Full Text] [Related]
7. [Dynamics of vagus nerve chronotropic effect during blockage of various M-cholinoreceptors].
Osadchiĭ OE; Pokrovskiĭ VM
Biull Eksp Biol Med; 1999 Mar; 127(3):252-5. PubMed ID: 10225091
[No Abstract] [Full Text] [Related]
8. [The antiparkinson activity of muscarinic antagonists depending on their selectivity for individual m-cholinoreceptor subtypes].
Kosmachev AB; Beliaev VA; Khrabrova AV; Fil'ko OA; Libman NM
Eksp Klin Farmakol; 1998; 61(5):3-5. PubMed ID: 9854621
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological properties of (2R)-N-[1-(6-aminopyridin-2-ylmethyl)piperidin-4-yl]-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamide: a novel mucarinic antagonist with M(2)-sparing antagonistic activity.
Hirose H; Aoki I; Kimura T; Fujikawa T; Numazawa T; Sasaki K; Sato A; Hasegawa T; Nishikibe M; Mitsuya M; Ohtake N; Mase T; Noguchi K
J Pharmacol Exp Ther; 2001 May; 297(2):790-7. PubMed ID: 11303071
[TBL] [Abstract][Full Text] [Related]
10. [Effect of pH on muscarinic antagonist selectivity].
Kosmachev AB; Iakhontova MB; Titkova TA; Fil'ko OA; Ramsh SM
Eksp Klin Farmakol; 2001; 64(3):29-32. PubMed ID: 11558434
[TBL] [Abstract][Full Text] [Related]
11. Role of muscarinic receptors, G-proteins, and intracellular messengers in muscarinic modulation of NMDA receptor-mediated synaptic transmission.
Aramakis VB; Bandrowski AE; Ashe JH
Synapse; 1999 Jun; 32(4):262-75. PubMed ID: 10332802
[TBL] [Abstract][Full Text] [Related]
12. Universal template approach to drug design: polyamines as selective muscarinic receptor antagonists.
Bolognesi ML; Minarini A; Budriesi R; Cacciaguerra S; Chiarini A; Spampinato S; Tumiatti V; Melchiorre C
J Med Chem; 1998 Oct; 41(21):4150-60. PubMed ID: 9767650
[TBL] [Abstract][Full Text] [Related]
13. [Subtypes and neuronal localization of muscarinic receptors in rat cerebral hemispheres].
Kosmachev AB; Podosinovikova NP; Solov'eva NE; Dolgo-Saburov VV
Eksp Klin Farmakol; 2000; 63(5):7-9. PubMed ID: 11109515
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationships of dimethindene derivatives as new M2-selective muscarinic receptor antagonists.
Böhme TM; Keim C; Kreutzmann K; Linder M; Dingermann T; Dannhardt G; Mutschler E; Lambrecht G
J Med Chem; 2003 Feb; 46(5):856-67. PubMed ID: 12593665
[TBL] [Abstract][Full Text] [Related]
15. Regulation of glutamate release from primary afferents and interneurons in the spinal cord by muscarinic receptor subtypes.
Zhang HM; Chen SR; Pan HL
J Neurophysiol; 2007 Jan; 97(1):102-9. PubMed ID: 17050831
[TBL] [Abstract][Full Text] [Related]
16. Selectivity profile of muscarinic toxin 3 in functional assays of cloned and native receptors.
Olianas MC; Ingianni A; Maullu C; Adem A; Karlsson E; Onali P
J Pharmacol Exp Ther; 1999 Jan; 288(1):164-70. PubMed ID: 9862767
[TBL] [Abstract][Full Text] [Related]
17. [The selectivity of the action of muscarinic agonists in vivo].
Kosmachev AB; Kosmacheva IM; Iankhotova MV; Kuleshov VI
Eksp Klin Farmakol; 1994; 57(2):6-8. PubMed ID: 8205054
[TBL] [Abstract][Full Text] [Related]
18. Expression of muscarinic receptor subtypes in salivary glands of rats, sheep and man.
Ryberg AT; Warfvinge G; Axelsson L; Soukup O; Götrick B; Tobin G
Arch Oral Biol; 2008 Jan; 53(1):66-74. PubMed ID: 17825245
[TBL] [Abstract][Full Text] [Related]
19. [The role of the muscarinic receptors in the pathogenesis of the convulsive state induced by korazol in rats].
Khobotova ZI; Mukovskiĭ LA; Kosmachev AB; Fil'ko OA; Filippov VN; Dolgo-Saburov VB
Eksp Klin Farmakol; 1997; 60(1):16-8. PubMed ID: 9162273
[TBL] [Abstract][Full Text] [Related]
20. Muscarinic acetylcholine receptors as CNS drug targets.
Langmead CJ; Watson J; Reavill C
Pharmacol Ther; 2008 Feb; 117(2):232-43. PubMed ID: 18082893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
